Precision BioSciences to Report First Quarter 2021 Financial Results on May 13, 2021

Rhea-AI Summary

Precision BioSciences, Inc. (Nasdaq: DTIL) will report its first quarter 2021 financial results and provide a business update on May 13, 2021. The company focuses on developing innovative allogeneic CAR T and in vivo gene correction therapies utilizing its proprietary ARCUS^® genome editing platform. This platform aims to enhance therapeutic safety and control, targeting genetic and infectious diseases for which current treatments are inadequate.

Positive

• Company focuses on allogeneic CAR T and gene correction therapies.
• ARCUS platform designed for therapeutic safety and control.

Negative

• None.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS^® genome editing platform, today announced it will publish first quarter 2021 financial results and provide a business update on Thursday, May 13, 2021.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS^® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210506005331/en/

FAQ

What are the upcoming financial results for Precision BioSciences (DTIL)?

Precision BioSciences will release its first quarter 2021 financial results on May 13, 2021.

What is the focus of Precision BioSciences (DTIL)?

Precision BioSciences focuses on developing allogeneic CAR T therapies and in vivo gene correction therapies.

What is the ARCUS platform used by Precision BioSciences (DTIL)?

The ARCUS platform is a proprietary genome editing technology designed with a focus on therapeutic safety and delivery.

What is the purpose of the upcoming business update for Precision BioSciences (DTIL)?

The business update will provide insights into the company's progress and developments regarding its product pipeline.